Adela Castro

2 weeks ago | rheumnow.com | Adela Castro

IL-17 inhibitors are an effective therapeutic for a broad spectrum of inflammatory and autoimmune diseases and its blockade has revolutionized management of diseases such as psoriasis, psoriatic arthritis and SpA. Currently, four IL-17 inhibitors are approved, particularly for the management of moderate-to-severe plaque psoriasis and spondyloarthropathies. Secukinumab and Ixekizumab are both monoclonal antibodies directly targeting IL-17A.

Feb 14, 2025 | rheumnow.com | Adela Castro

The benefits of combination therapy are well known in rheumatoid arthritis with the use of conventional and biologic DMARDs, yet data has been conflicting in psoriatic arthritis (PsA). Despite various and efficacious options for management of PsA there is still an unmet need for patients with inadequate responses to current therapies or difficult-to-treat disease. The role of dual biologic therapy targeting different inflammatory pathways has become an area of great interest in the field.

Feb 11, 2025 | rheumnow.com | Adela Castro

The advent of artificial intelligence (AI) continue to amaze us in this changing world and in multiple areas of medicine. As an evolving science, rheumatology has also been introduced to AI where interesting applications seem to enhance patient care. In the specific case of rheumatoid arthritis (RA), it is known that despite different effective management options, there are still challenges predicting individual patient responses to therapies.

Nov 19, 2024 | rheumnow.com | Adela Castro

Different factors are known to influence disease characteristics and outcomes in psoriatic arthritis (PsA). Recently, there is new evidence that sex-related differences play a role not only in disease manifestations but also in efficacy and safety of treatments as well as outcomes and prognosis. Although PsA occurs in males and females at similar rates, clinical manifestations and outcomes differ between sexes, yet still few randomized controlled trials report sex-disaggregated results.

Nov 16, 2024 | rheumnow.com | Adela Castro

Axial spondyloarthritis (axSpA) is a chronic inflammatory disease primarily affecting the spine and sacroiliac joints, causing back pain, stiffness, and reduced mobility. The disease includes both non-radiographic axSpA and ankylosing spondylitis (AS), distinguished by the presence or absence of visible damage on imaging like X-rays.